FDA Approves TAMSULOSIN HYDROCHLORIDE — EXELAN PHARMACEUTICALS, INC.

Exelan Pharmaceuticals has received FDA approval for the ANDA087110, expanding its portfolio with the oral treatment Tamsulosisin Hydrochloride. This clearance provides Exelan with a commercial opportunity to compete in the benign prostatic hyperplasia market while potentially extending the patent life of the branded reference product.